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Abstract
We comment on the recent report entitled “Platelet Studies in Autism Spectrum Disorder Patients and First-Degree
Relatives” [Molecular Autism 2015;6:57]. We find it commendable that the authors have investigated platelet factors
potentially involved in the well-replicated observation of platelet hyperserotonemia in autism. However, we believe
the results need a fuller discussion in the context of prior studies, think that certain aspects of the interpretation
need to be reassessed, and attempt to provide a framework for further research in this area.
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Commentary
We would like to comment on the recent paper of Bijl
and colleagues entitled “Platelet Studies in Autism
Spectrum Disorder Patients and First-Degree Relatives”
[1]. We think the authors should be commended for
attempting to understand the mechanism(s) underlying
the well-replicated platelet hyperserotonemia of autism,
for their focus on platelet functioning, and for the size
of the sample studied. However, we believe that (1) the
comparison to prior studies of platelet counts, morph-
ology, and functioning in pediatric and autism and aut-
ism spectrum disorder (ASD) samples should be more
complete and (2) some aspects of the interpretation of
results need to be corrected. Before discussing specific
findings and issues, we will give a brief overview of the
origins and disposition of blood, plasma, and platelet
serotonin (5-hydroxytryptamine (5-HT)) and of the
platelet hyperserotonemia of autism.
Platelet 5-HT
Nearly all blood 5-HT is located in the platelet, with
only about 0.1 % usually being found free in the plasma.
Thus, concentrations of 5-HT in carefully prepared and
accurately assayed platelet-poor plasma (PPP) appear to
be approximately 100–200 pg/mL compared to typical
group mean whole blood levels in healthy controls of
about 150 ng/mL (~1000-fold higher than PPP). When
expressed on a per platelet basis, mean 5-HT levels in
whole blood or in platelet-rich plasma are about 600 ng
per billion platelets (i.e., typical adult whole blood plate-
let counts are 0.25–0.30 billion/mL and the PRP platelet
count is often adjusted to 0.25 billion/mL before use in
platelet function tests). The 5-HT found in blood/plate-
lets originates predominantly from enterochromaffin
cells of the gut and is taken up from the plasma
throughout the platelets’ 8- to 10-day lifespan via the
5-HT transporter. Platelet 5-HT is localized in the
dense granule and is released along with ATP during
aggregation and can augment aggregation through the
stimulation of platelet membrane 5-HT2A receptors.
Hyperserotonemia of autism
Group mean concentrations of blood 5-HT in ASD
groups are typically reported to be 25–50 % higher than
in healthy controls, and levels do not appear to be
related to intellectual disability [2–6]. Although this
“hyperserotonemia” was first reported in 1961 [7] and
has been thoroughly characterized over the years, there
is still frustratingly little that can be said about the
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mechanism of the elevation. Simply put, it can be sug-
gested that the elevation in 5-HT is either due to the
platelet being exposed to higher levels of 5-HT or to
some alteration in the platelet or its handling of 5-HT.
The measures employed by Bijl et al. are relevant to both
of these possibilities.
Observation of increased platelet count in ASD
Bijl and colleagues observed group mean whole blood
platelet counts that were 12 % higher in ASD compared
to pediatric controls. Some prior studies have also
reported slight but statistically significant elevations in
mean platelet counts in autism [4, 8], while others have
not observed significant differences in platelet count
[9, 10]. Some of the discrepancies might be due to
the reported substantial effects of age and/or puberty,
with lower platelet counts observed for adolescents
and young adults compared to pre-pubertal children
(e.g., [4, 10, 11]). Given the substantial difference in
mean age in their ASD and pediatric control groups
(11.9 versus 15.6 years), it would have been desirable
for Bijl and colleagues to covary or better match for
age and to make separate diagnostic group compari-
sons within the pre and the post-pubertal subgroups.
Their finding of only a slight and non-significant
trend to lower mean platelet volume (MPV) in ASD
is consistent with most prior reports. When McBride
et al. [4] calculated the total platelet volume (TPV)
by multiplying an individual’s mean platelet volume
by the platelet count; mean TPVs were very similar in
ASD and control groups. To summarize, it appears
that little if any of the increase in platelet 5-HT in
autism can be attributed to either increased platelet
counts or differences in platelet size.
Observation of higher platelet-poor plasma 5-HT in ASD
It should be pointed out that the values for PPP 5-HT
(~10–20 ng/mL) reported in Bijl et al. are much too high
to represent in any manner the much lower levels of 5-
HT actually present in PPP. As has been previously dis-
cussed at length [12, 13], difficulties in preparing PPP
without any platelet contamination or platelet 5-HT
release and problems with accurately measuring the low
levels of 5-HT present have made nearly all prior mea-
surements of PPP 5-HT falsely and markedly elevated
and useless. The two studies providing the apparent best
estimates of PPP 5-HT in autism (and thereby an index
of platelet exposure to 5-HT) found similar levels in aut-
ism and contrast groups [14, 15]. As stated above, the
finding of higher whole blood or platelet 5-HT in ASD
has been well replicated, and it is safe to assume that the
ASD group studied by Bijl and colleagues also had an
elevated group mean platelet 5-HT concentration. How-
ever, their reported PPP values say nothing about the
extent of the (presumed) 5-HT elevation in this group
or about the platelet or PPP 5-HT levels in a particular
individual. While their PPP 5-HT measurements and the
associated correlations and group comparisons should
be disregarded, the authors are almost certainly correct
in saying that their observation of comparatively greater
release and aggregation in the control group in response
to epinephrine, ADP, or collagen cannot be due to
increased plasma 5-HT levels in controls.
Observation of lower aggregation and release in ASD
As just mentioned, Bijl and colleagues observed that the
ASD group had lower platelet aggregation and dense
granule (ATP) release in response to epinephrine, ADP,
and collagen stimulation. As the authors acknowledge,
these observations are confounded by the lack of an age-
matched (pediatric) control group for the aggregation
and release experiments. However and on their behalf, it
can be pointed out that there do not appear to be age-
related changes in platelet responses to aggregating
agents after the neonatal period to the extent this has
been studied in platelet-rich plasma [16] and in whole
blood [17]. It would have been informative to compare
their findings to those of Saffai-Kutti et al. [18] and
McBride et al. [19], the latter of whom reported reduced
5-HT augmentation of ADP-induced aggregation in ASD
versus controls. This lower augmentation was observed
without any group difference in the concentration of
ADP required to produce a sub-threshold (15–20 %)
aggregation response. Although the McBride et al. obser-
vation of similar sensitivity to ADP is at some variance
with the Bijl et al. report of lower ADP-induced aggrega-
tion and release, it would be of fundamental interest to
assess the relationship between platelet levels of 5-HT
and the aggregation and release responses. In the McBride
et al. report, an inverse relationship was seen between
platelet 5-HT level and blunted response to 5-HT aug-
mentation, leading to the suggestion that reduced platelet
5-HT2A receptor functioning might somehow lead to
greater platelet 5-HT [19]. As an aside, it would also be of
interest to know what sort of parent-sib and sib-sib corre-
lations are found with the platelet functioning measures
given the high heritability reported for platelet 5-HT [20].
Interpretation of platelet functioning results
We find it necessary to correct the statement of the
discussion that reads “Since we find reduced platelet ag-
gregation and secretion in ASD, we hypothesize that the
increased serotonin levels are caused by reduced uptake
rather than by increased release from platelets.” The au-
thors appear to have confused platelet and plasma 5-HT
and have failed to appreciate that while platelet 5-HT is
consistently found to be elevated in ASD groups, the min-
iscule PPP 5-HT values are probably not increased in ASD
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[14, 15]. It is clear that the increased platelet 5-HT levels
of ASD can in no way be attributed to either reduced up-
take or increased release. Rather, and quite the contrary, it
is possible that either increased uptake or decreased re-
lease, or both, could contribute to the platelet hypersero-
tonemia. While studies of platelet 5-HT uptake rates and
5-HT transporter sites, as well as associated genes, have
suggested that increased uptake might contribute to the
hyperserotonemia, the extent of that contribution remains
unclear (for reviews, see references [2, 3, 21, 22]).
Although we find some problems with the Bijl et al.
paper, we do think the simultaneous measurement of 5-
HT levels and of indices of platelet functioning is a valu-
able approach. The paper has served to bring attention
to important issues related to possible mechanisms of
the platelet hyperserotonemia of ASD and to the poten-
tial utility of the platelet measures in ASD. It is clear
that, along with the platelet functioning measures, future
studies in this area should assay platelet 5-HT levels and
that this is probably best and most simply done using
whole blood samples. Concomitant careful measure-
ments of PPP 5-HT would add to the only limited data
presently available regarding the platelet’s exposure to
5-HT. A possible contributor to the platelet hyperser-
otonemia of autism that has been given little atten-
tion is platelet lifespan and its determination would
be interest. The search for specific behavioral or biological
associations with platelet 5-HT levels in autism has
been largely futile to date, but might benefit from
new approaches in behavioral assessment and from
the application of neurophysiological methodologies.
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